Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualization of therapy using viral markers.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association - 1 Jan 1995

Merigan T

Abstract excerpt

Early intervention with a combination of drugs is generally accepted as the way forward in the management of HIV infection. In general, combination therapy should include agents that demonstrate additive or synergistic activity, do not have similar side-effect profiles, and avoid cross-resistance. Use of these criteria will no doubt lead to the development of more effective combinations. However, it is well known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to DNA, Viral
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to HIV Infections

Share to Phenotype

Share to RNA, Viral

Source

Identifiers

PMID: 8595507

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualization of therapy using viral markers.PMID 8595507Read ↗

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.Semantic proximity Read ↗

The role of phenotyping and replication capacity in anti-HIV therapeutics.Semantic proximity Read ↗

Incorporating novel virologic tests into clinical practice.Semantic proximity Read ↗

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.Semantic proximity Read ↗

Viral phenotype and genotype as markers in clinical trials.Semantic proximity Read ↗

Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.Semantic proximity Read ↗

Phenotypic resistance testing.Semantic proximity Read ↗

Role of HIV phenotypic assays in the management of HIV infection.Semantic proximity Read ↗

Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.Semantic proximity Read ↗

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.Semantic proximity Read ↗

Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.Semantic proximity Read ↗

Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.